UK markets close in 6 hours 17 minutes

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
48.20-0.82 (-1.66%)
As of 06:38PM GMT. Market open.
Full screen
Previous close49.02
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume22,500
Avg. volumeN/A
Market cap5.201M
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-0.58
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Here's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price Strength

    If you are looking for stocks that are well positioned to maintain their recent uptrend, Basilea Pharmaceutica AG (BPMUF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

  • Globe Newswire

    Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

    Sale of Basilea’s novel preclinical CLK kinase inhibitorsTotal payments of up to CHF 354 million Third oncology transaction as part of Basilea’s strategic refocusing on anti-infectives Basel/Allschwil, Switzerland, November 2, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Twentyeight-Seven The

  • Globe Newswire

    ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)

    Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to daptomycin, meeting primary endpoint and demonstrating similar secondary efficacy outcomes Basel/Allschwil, Switzerland, October 24, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that data from the succ